Sensei Biotherapeutics reports favorable Phase 1/2 data for SNS-101 at SITC 2023

Sensei Biotherapeutics, Inc.

SNS-101 dose escalation (13 patients): well-tolerated, no DLTs, no CRS; only one related AE (Grade 2 dermatitis).
Pharmacokinetics: dose-proportional exposure, linear elimination, no target-mediated drug disposition; supports every-three-week dosing.
SNS-101 achieved dose levels >10x higher than a competitor VISTA antibody that was halted due to CRS, suggesting best-in-class potential.
Expected data readouts: initial combo safety/PK data Q1 2024, topline monotherapy Q2 2024, topline combo later in 2024.
Late-breaking poster at SITC 2023 on Nov 4; data supports conditionally active VISTA-blocking approach.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.